Case Study – Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis

Challenge

Increasing global access to robust liquid biopsy technology

Solution

MSK-ACCESS® powered with SOPHiA DDM™

Country

U.S.A

Memorial Sloan Kettering Cancer Center (MSK) is a world leading institution for cancer treatment and research. We’re collaborating with MSK to expand access to precision cancer analysis capabilities worldwide.

Watch Video

The people of MSK are united by a singular mission: ending cancer for life. Their specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at the Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue the mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, they have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years1.

Challenge

To expand access to MSK-ACCESS® – a highly validated, non-invasive liquid biopsy test for cancer genomic profiling and disease monitoring – by scaling the solution and making it available outside of MSK.

Approach

MSK-ACCESS® is a cancer genomic profiling test notably based on paired analysis of matched tumor-normal samples. It enables MSK to provide rapid, less-invasive tumor profiling while delivering informative results that help clarify treatment options as well as identify resistance mechanisms and tumor type. Studies have shown that treatment decisions based on MSK-ACCESS® lead to better outcomes, resulting in its routine use as a first-line test for incoming patients at the cancer center². MSK-ACCESS® profiles 147 key cancer-associated genes and enables SNVs, Indels, copy number and structural variants to be reported with high sensitivity.

Through a collaboration between SOPHiA GENETICS and MSK, MSK-ACCESS® will be available to more people via the decentralized, technology agnostic SOPHiA DDM™ Platform. The Platform’s cloud-based analysis, interpretation and reporting workflow streamlines locally performed analysis, allowing labs to retain control of their data and samples.

Solution

Working together, we have created MSK-ACCESS® powered with SOPHiA DDM™ which provides a true sample-to-report workflow featuring key cancer-associated gene content curated by MSK experts, and supporting a turnaround time of ~5 days.

The workflow employs the same matched tumor-normal approach to reduce noise and maximizes insights for longitudinal monitoring, all while streamlining analysis, interpretation and reporting. Demonstrated 99.4% end-to-end concordance with MSK-ACCESS® provides trusted analytical performance.

References

1. MSK. About Us. Available at: https://www.mskcc.org/about
2. Jee J., et al., Nature Med., 2022

MSK-ACCESS® powered with SOPHiA DDM™ is for research use only – not for use in diagnostic procedures.

Watch as Brian Loomis, Director of Clinical Next-Generation Sequencing at MSK, and Florian Klemm, Technical Product Manager/Genomic Research Expert at SOPHiA GENETICS, showcase the results of the collaboration

In a webinar hosted by The Pathologist, Brian describes the clinical implementation and benefits of MSK-ACCESS® at MSK.
Florian presents analytical performance data that demonstrates the concordance between single-site MSK-ACCESS® and the decentralized MSK-ACCESS® powered with SOPHiA DDM™.

Watch Webinar

Related Case Studies

Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis Read More

Genomic Diagnostics, Australia Read More

TomaLab Advanced Biomedical Assays Read More

1 2 3 … 5 Next »

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services